Literature DB >> 29504252

Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease.

George L Bakris1, Lin Zhao2, Stuart Kupfer2, Attila Juhasz3, Michie Hisada2, Eric Lloyd2, Suzanne Oparil4.   

Abstract

An open-label, long-term study evaluated safety and tolerability of azilsartan medoxomil/chlorthalidone (AZL-M/CLD) vs olmesartan/hydrochlorothiazide (OLM/HCTZ) in hypertensive participants with stage 3 chronic kidney disease. Initial therapy was AZL-M/CLD 20/12.5 mg (n = 77) or OLM/HCTZ 20/12.5 mg (n = 76), but could be up-titrated (AZL-M/CLD to 40/25 mg; OLM/HCTZ to 40/25 mg [US] or 20/25 mg [Europe]) with other agents added during weeks 4-52. Primary endpoint was proportion of participants with ≥ 1 adverse event (AE) through week 52. Baseline demographics were similar. AEs did not differ between groups (88.3%, AZL-M/CLD vs 76.3%, OLM/HCTZ; P = .058). AZL-M/CLD showed greater systolic BP reductions after initial dosing (P = .037) but not during long-term follow-up (P = .588). A greater proportion of participants up-titrated to the highest dose with OLM/HCTZ (48.7%) vs AZL-M/CLD (29.9%) (P = .021) and were taking additional antihypertensive medications (26.3% vs 16.9%). Both AZL-M/CLD and OLM/HCTZ showed similar efficacy and tolerability. ©2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  cardiovascular; hypertension; kidney; nephropathy; outcomes; renal

Mesh:

Substances:

Year:  2018        PMID: 29504252      PMCID: PMC8031057          DOI: 10.1111/jch.13230

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  25 in total

1.  Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure.

Authors:  Michael E Ernst; Barry L Carter; Chris J Goerdt; Jennifer J G Steffensmeier; Beth Bryles Phillips; M Bridget Zimmerman; George R Bergus
Journal:  Hypertension       Date:  2006-01-23       Impact factor: 10.190

Review 2.  Management of hypertension: evidence from the Blood Pressure Lowering Treatment Trialists' Collaboration and from major clinical trials.

Authors:  John Chalmers; Hisatomi Arima
Journal:  Pol Arch Med Wewn       Date:  2009-06

Review 3.  The Kidney in Hypertension.

Authors:  Hillel Sternlicht; George L Bakris
Journal:  Med Clin North Am       Date:  2017-01       Impact factor: 5.456

4.  Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study.

Authors:  S S Franklin; W Gustin; N D Wong; M G Larson; M A Weber; W B Kannel; D Levy
Journal:  Circulation       Date:  1997-07-01       Impact factor: 29.690

5.  Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study.

Authors:  Marcello Tonelli; Paul Muntner; Anita Lloyd; Braden J Manns; Scott Klarenbach; Neesh Pannu; Matthew T James; Brenda R Hemmelgarn
Journal:  Lancet       Date:  2012-06-19       Impact factor: 79.321

6.  Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension.

Authors:  William C Cushman; George L Bakris; William B White; Michael A Weber; Domenic Sica; Andrew Roberts; Eric Lloyd; Stuart Kupfer
Journal:  Hypertension       Date:  2012-06-18       Impact factor: 10.190

7.  Chlorthalidone for poorly controlled hypertension in chronic kidney disease: an interventional pilot study.

Authors:  Rajiv Agarwal; Arjun D Sinha; Maria K Pappas; Farah Ammous
Journal:  Am J Nephrol       Date:  2014-02-11       Impact factor: 3.754

Review 8.  The double challenge of resistant hypertension and chronic kidney disease.

Authors:  Patrick Rossignol; Ziad A Massy; Michel Azizi; George Bakris; Eberhard Ritz; Adrian Covic; David Goldsmith; Gunnar H Heine; Kitty J Jager; Mehmet Kanbay; Francesca Mallamaci; Alberto Ortiz; Raymond Vanholder; Andrzej Wiecek; Carmine Zoccali; Gérard Michel London; Bénédicte Stengel; Denis Fouque
Journal:  Lancet       Date:  2015-10-17       Impact factor: 79.321

9.  Usual blood pressure, peripheral arterial disease, and vascular risk: cohort study of 4.2 million adults.

Authors:  Connor A Emdin; Simon G Anderson; Thomas Callender; Nathalie Conrad; Gholamreza Salimi-Khorshidi; Hamid Mohseni; Mark Woodward; Kazem Rahimi
Journal:  BMJ       Date:  2015-09-29

10.  Effects of azilsartan medoxomil compared with olmesartan and valsartan on ambulatory and clinic blood pressure in patients with type 2 diabetes and prediabetes.

Authors:  William B White; René H Cuadra; Eric Lloyd; George L Bakris; Stuart Kupfer
Journal:  J Hypertens       Date:  2016-04       Impact factor: 4.844

View more
  2 in total

1.  Long-term efficacy and tolerability of azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide in chronic kidney disease.

Authors:  George L Bakris; Lin Zhao; Stuart Kupfer; Attila Juhasz; Michie Hisada; Eric Lloyd; Suzanne Oparil
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-03-04       Impact factor: 3.738

2.  Treatment of hypertension in CKD patients with azilsartan/chlorthalidone vs olmesartan/hydrochlorothiazide.

Authors:  Walter M van der Merwe
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-03-04       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.